ICCC
Price
$10.44
Change
-$0.08 (-0.76%)
Updated
Oct 22 closing price
Capitalization
94.82M
21 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$1.74
Change
-$0.01 (-0.57%)
Updated
Oct 22 closing price
Capitalization
124.63M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ICCC vs NKTX

ICCC vs NKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ICCC vs. NKTX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Hold and NKTX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ICCC with price predictions
Oct 22, 2026

ICCC in downward trend: price may drop because broke its higher Bollinger Band on October 13, 2026

ICCC broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 33 of the 41 cases the stock fell afterwards. This puts the odds of success at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ICCC moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 64 cases where ICCC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on ICCC as a result. In 94 of 123 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for ICCC just turned positive on October 13, 2026. Looking at past instances where ICCC's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

ICCC moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 108 of 140 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.022) is normal, around the industry mean (2.973). ICCC's P/E Ratio (130.500) is considerably higher than the industry average of (-1.705). Projected Growth (PEG Ratio) (8.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.847) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for NKTX with price predictions
Oct 22, 2026

NKTX in -3.33% downward trend, declining for three consecutive days on October 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NKTX declined for three days, in 307 of 343 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for NKTX turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

NKTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

The Aroon Indicator for NKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.503) is normal, around the industry mean (2.973). P/E Ratio (-1.094) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ICCC vs NKTX: Fundamental Ratings
ICCC
NKTX
OUTLOOK RATING
1..100
8752
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
8897
PRICE GROWTH RATING
1..100
4087
P/E GROWTH RATING
1..100
215
SEASONALITY SCORE
1..100
6550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (39) in the null industry is somewhat better than the same rating for ICCC (100) in the Medical Specialties industry. This means that NKTX’s stock grew somewhat faster than ICCC’s over the last 12 months.

ICCC's Profit vs Risk Rating (91) in the Medical Specialties industry is in the same range as NKTX (100) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.

ICCC's SMR Rating (88) in the Medical Specialties industry is in the same range as NKTX (97) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.

ICCC's Price Growth Rating (40) in the Medical Specialties industry is somewhat better than the same rating for NKTX (87) in the null industry. This means that ICCC’s stock grew somewhat faster than NKTX’s over the last 12 months.

ICCC's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as NKTX (15) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICCCNKTX
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ICCC: $10.52 vs. NKTX: $1.75)
Brand notoriety: ICCC and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICCC: 52% vs. NKTX: 135%
Market capitalization -- ICCC: $94.82M vs. NKTX: $124.63M
ICCC [@Biotechnology] is valued at $94.82M. NKTX’s [@Biotechnology] market capitalization is $124.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICCC’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).

  • ICCC’s FA Score: 1 green, 4 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ICCC and NKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 6 TA indicator(s) are bullish while NKTX’s TA Score has 4 bullish TA indicator(s).

  • ICCC’s TA Score: 6 bullish, 4 bearish.
  • NKTX’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, ICCC is a better buy in the short-term than NKTX.

Price Growth

ICCC (@Biotechnology) experienced а -2.14% price change this week, while NKTX (@Biotechnology) price change was -13.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ICCC is expected to report earnings on Nov 12, 2026.

NKTX is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ICCC
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ICCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
-0.76%
NKTX - ICCC
43%
Loosely correlated
-0.57%
JANX - ICCC
27%
Poorly correlated
+0.77%
BOLT - ICCC
26%
Poorly correlated
-1.45%
NERV - ICCC
24%
Poorly correlated
+0.42%
IMMP - ICCC
23%
Poorly correlated
-3.66%
More

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-0.57%
EDIT - NKTX
51%
Loosely correlated
-0.80%
CRSP - NKTX
49%
Loosely correlated
-1.01%
VIR - NKTX
47%
Loosely correlated
-1.32%
PROK - NKTX
47%
Loosely correlated
-0.69%
RCKT - NKTX
46%
Loosely correlated
+5.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RSDE24.160.10
+0.42%
FT Vest U.S. Equity Equal Weight Buffer ETF - December (RSDE)
BDJ9.57-0.05
-0.52%
BlackRock Enhanced Equity Dividend Trust
QQHG65.82-1.20
-1.79%
Invesco QQQ Hedged Advantage ETF (QQHG)
CAML39.30-1.30
-3.20%
Congress Large Cap Growth ETF (CAML)
NVII22.62-1.12
-4.72%
REX NVDA Growth & Income ETF